| 标题 |
Tislelizumab and hypofractionated radiotherapy plus nab‑paclitaxel/gemcitabine as conversion therapy for BRPC/LAPC: a phase Ⅱ trial with dynamic biomarker monitoring |
| 网址 | |
| DOI |
10.1158/1078-0432.CCR-25-2461
doi
|
| 求助人 | |
| 下载 | 暂无链接,等待应助者上传 |
PDF的下载单位、IP信息已删除
(2025-6-4)